Mineralys Therapeutics To Participate In Upcoming Investor Conferences
| Guggenheim Healthcare Innovation Conference | |
| Date: | Tuesday, November 10, 2026 |
| Time: | 2:30pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
| Stifel Healthcare Conference | |
| Date: | Thursday, November 12, 2026 |
| Time: | 8:40am ET |
| Format: | Fireside Chat |
| Webcast Link | |
| 9 th Annual Evercore Healthcare Conference | |
| Date: | Tuesday, December 1, 2026 |
| Time: | 1:45pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
The live webcasts and archives of these fireside chats can also be accessed on the“News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit . Follow Mineralys on LinkedIn, X and Bluesky.
Contact:
Investor Relations ...
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: ...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment